Identification of new process-related impurity in the key intermediate in the synthesis of TCV-116

1. S. Kantipudi and A. Khasnis, Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme, Cong. Heart Fail.10 (2004) 114–116; https://doi.org/10.1111/j.1527-5299.2004.02799.x10.1111/j.1527-5299.2004.02799.xSearch in Google Scholar

2. R. Vellalacheruvu, R. S. Leela, L. K. Ravindranath and M. Thummisetty, Novel route for synthesis of antihypertensive activity of tetrazole analogues as a carbamate and urea derivatives, Org. Med. Chem. IJ.3 (2017) Article ID 555609 (10 pages); https://doi.org/10.19080/OMCIJ.2017.03.55560910.19080/OMCIJ.2017.03.555609Search in Google Scholar

3. The International Council for Harmonisation (ICH), Q3A(R2) Guideline. Impurities in New Drug Substances, October 2006; http://www.ich.org/products/guidelines/quality/quality-single/article/impurities-in-new-drug-substances.html; last access March 24, 2018.Search in Google Scholar

4. D. J. Snodin and S. D. McCrossen, Mutagenic impurities in pharmaceuticals. A critique of the derivation of the cancer TTC (Threshold of Toxicological Concern) and recommendations for structural-class-based limits, Regul. Toxicol. Pharm.67 (2013) 299–316; https://doi.org/10.1016/j.yrtph.2013.08.01410.1016/j.yrtph.2013.08.01423988886Search in Google Scholar

5. S. Singh, T. Handa, M. Narayaaani, A. Sahu, M. Junwal and R. P. Shah, A critical review on the use of modem sophisticated hyphenated tools in the characterization of impurities and degradation products, J. Pharm. Biomed. Anal.69 (2012) 148–173; https://doi.org/10.1016/j.jpba.2012.03.04410.1016/j.jpba.2012.03.04422521633Search in Google Scholar

6. S. Mehta, R. P. Shah, R. Priyadarshi and S. Singh, LC and LC–MS/TOF studies on stress degradation behaviour of candesartan cilexetil, J. Pharm. Biomed.52 (2010) 345–354; https://doi.org/10.1016/j.jpba.2009.05.00610.1016/j.jpba.2009.05.00619505786Search in Google Scholar

7. S. Sangwan, T. Panda, K. Nayyar, S. K. Dewan and R. K. Thaper, Synthesis and characterization of impurities of a common and advanced intermediate of candesartan and azilsartan antihypertensive drugs, Int. Res. J. Pure Appl. Chem.5 (2015) 140–149; https://doi.org/10.9734/irjpac/2015/1316210.9734/IRJPAC/2015/13162Search in Google Scholar

8. B. Raman, B. A. Sharma, G. Mahale, D. Singh and A. Kumar, Investigation and structural elucidation of a process related impurity in candesartan cilexetil by LC/ESI-ITMS and NMR, J. Pharm. Biomed.56 (2011) 256–263; https://doi.org/10.1016/j.jpba.2011.05.02410.1016/j.jpba.2011.05.02421664089Search in Google Scholar

9. N. A. Kakasaheb, K. Ramakrishna and V. Srinivasarao, Method development and validation by GC-MS for quantification of 1-chloroethyl cyclohexyl carbonate as a genotoxic impurity in candesartan cilexetil drug substance, Int. J. Pharm. Pharm. Sci.6 (2014) 370–372.Search in Google Scholar

10. D. Henschler, Toxicity of chlorinated organic compounds: effects of the introduction of chlorine in organic molecules, Angew. Chem. Int. Ed.33 (1994) 1920–1935; https://doi.org/10.1002/anie.19941920110.1002/anie.199419201Search in Google Scholar

11. J.-P. Senet, G. Sennyey and G. P. Wooden, A convenient new route to 1-haloalkyl carbonates, Synthesis5 (1988) 407–410; https://doi.org/10.1055/s-1988-2759610.1055/s-1988-27596Search in Google Scholar

12. Y. V. Shurukhin, N. A. Klyuev and I. I. Grandberg, Similarities between thermolysis and mass spectrometric fragmentation of tetrazoles (review), Chem. Heterocyc. Compd.21 (1985) 605–620.10.1007/BF00515057Search in Google Scholar

13. M. Peng, S. Li, J. Wu, Y. Guo, S. Cao and Y. Zhao, Fragmentation studies of sartans by electrospray ionization mass spectrometry, J. Mass Spectrom.52 (2017) 591–596; https://doi.org/10.1002/jms.396510.1002/jms.396528677141Search in Google Scholar

14. I. Dams, A. Ostaszewska, M. Puchalska, J. Chmiel, P. Cmoch, I. Bujak, A. Białońska and V. J. Szczepek, Synthesis and physicochemical characterization of the process-related impurities of olmesartan medoxomil. Do 5-(biphenyl-2-yl)-1-triphenylmethyltetrazole intermediates in sartan syntheses exist?, Molecules20 (2015) 21346–21363; https://doi.org/10.3390/molecules20121976210.3390/molecules201219762633223026633332Search in Google Scholar